Evidence map›Paper›PMID 35852437›Full record

ArticleThe oncologist2022

Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network.

Dora Dias-Santagata, Rebecca S Heist, Adam Z Bard, Annacarolina F L da Silva, Ibiayi Dagogo-Jack, Valentina Nardi, Lauren L Ritterhouse, Laura M Spring, Nicholas Jessop, Alexander A Farahani and 40 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Implementation of the precision oncology program in catalonia's public health system: results, lessons learned, and future prospects.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Slide-to-Slide Tissue Transfer and Array Assembly From Limited Samples for Comprehensive Molecular Profiling.Laboratory investigation; a journal of technical methods and pathology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

50 authors at 2 institutions in 1 country.

Dora Dias-SantagataDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-1174-3972
Rebecca S HeistMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-7397-2009
Adam Z BardDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Annacarolina F L da SilvaDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Ibiayi Dagogo-JackMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Valentina NardiDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Lauren L RitterhouseDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Laura M SpringMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Nicholas JessopDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Alexander A FarahaniDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Mari Mino-KenudsonDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Jill AllenMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Lipika GoyalMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Aparna ParikhMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Joseph MisdrajiDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Ganesh ShankarDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Justin T JordanMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Maria Martinez-LageDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Matthew FroschDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Timothy GraubertMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Amir T FathiMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Gabriela S HobbsMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Robert P HasserjianDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Noopur RajeMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Jeremy AbramsonMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Joel H SchwartzMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Ryan J SullivanMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
David MillerMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-9736-9119
Mai P HoangDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Steven IsakoffMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Amy LyDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Sara BouberhanMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Jaclyn WatkinsDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Esther OlivaDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Lori WirthMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-2629-2289
Peter M SadowDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-1036-6367
William FaquinDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Gregory M CoteMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-3565-9302
Yin P HungDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Xin GaoMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Chin-Lee WuDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Salil GargDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Miguel RiveraDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Long P LeDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
A John IafrateDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Dejan JuricMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Ephraim P HochbergMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Jeffrey ClarkMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Aditya BardiaMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-4885-1157
Jochen K LennerzDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-2434-4978
Harvard University · USBrigham and Women's Hospital · US

Funding

Strategies to Overcome Immune Resistance in Head and Neck CancersP01CA240239 · NCI · YALE UNIVERSITY · PI PAI, SARA ISABEL · 2019 to 2023
$8.4M
Illuminating the evolutionary history of colorectal cancer metastasis: basic principles and clinical applicationsR37CA225655 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI NAXEROVA, KAMILA · 2018 to 2024
$3.0M
NCI NIH HHS P01 CA240239NCI NIH HHS R37 CA225655
6 · The paper itself

Abstract

backgroundPrecision oncology relies on molecular diagnostics, and the value-proposition of modern healthcare networks promises a higher standard of care across partner sites. We present the results of a clinical pilot to standardize precision oncology workflows.

methodsWorkflows are defined as the development, roll-out, and updating of disease-specific molecular order sets. We tracked the timeline, composition, and effort of consensus meetings to define the combination of molecular tests. To assess clinical impact, we examined order set adoption over a two-year period (before and after roll-out) across all gastrointestinal and hepatopancreatobiliary (GI) malignancies, and by provider location within the network.

resultsDevelopment of 12 disease center-specific order sets took ~9 months, and the average number of tests per indication changed from 2.9 to 2.8 (P = .74). After roll-out, we identified significant increases in requests for GI patients (17%; P < .001), compliance with testing recommendations (9%; P < .001), and the fraction of "abnormal" results (6%; P < .001). Of 1088 GI patients, only 3 received targeted agents based on findings derived from non-recommended orders (1 before and 2 after roll-out); indicating that our practice did not negatively affect patient treatments. Preliminary analysis showed 99% compliance by providers in network sites, confirming the adoption of the order sets across the network.

conclusionOur study details the effort of establishing precision oncology workflows, the adoption pattern, and the absence of harm from the reduction of non-recommended orders. Establishing a modifiable communication tool for molecular testing is an essential component to optimize patient care via precision oncology.

Indexed as

NeoplasmsDelivery of Health CareHumansMedical OncologyPrecision MedicineWorkflowbiomarkerscompanion diagnosticstargeted therapyutilization management

Identifiers

PMID35852437
PMCPMC9632318
OpenAlexW4286216476

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.